Publicaciones en colaboración con investigadores/as de National Cancer Institute (5)

2021

  1. Minimal residual disease in Myeloma: Application for clinical care and new drug registration

    Clinical Cancer Research, Vol. 27, Núm. 19, pp. 5195-5212

2016

  1. Assessment of minimal residual disease in myeloma and the need for a consensus approach

    Cytometry Part B - Clinical Cytometry, Vol. 90, Núm. 1, pp. 21-25

  2. Consensus guidelines for myeloma minimal residual disease sample staining and data acquisition

    Cytometry Part B - Clinical Cytometry, Vol. 90, Núm. 1, pp. 26-30

  3. Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting

    Cytometry Part B - Clinical Cytometry, Vol. 90, Núm. 1, pp. 31-39

2014

  1. Flow cytometry detection of minimal residual disease in multiple myeloma: Lessons learned at FDA-NCI roundtable symposium

    American Journal of Hematology